PMID- 16344258 OWN - NLM STAT- MEDLINE DCOM- 20060914 LR - 20220330 IS - 1538-4721 (Print) IS - 1538-4721 (Linking) VI - 4 IP - 4 DP - 2005 TI - Intraoperative (125)I Vicryl mesh brachytherapy after sublobar resection for high-risk stage I non-small cell lung cancer. PG - 278-85 AB - PURPOSE: To assess the feasibility and outcomes of (125)I Vicryl mesh brachytherapy after sublobar resection in stage I non small cell lung cancer (NSCLC) patients with poor pulmonary function. METHODS AND MATERIALS: Between January 1997 and July 2004, patients with poor cardiopulmonary reserve who had stage IA and IB (T1-2 N0 M0) NSCLC and a forced expiratory volume in 1s (FEV(1)) of > micro=0.6L were considered for limited surgical resection either by an open or video-assisted thoracoscopic procedure and for a subsequent (125)I Vicryl mesh brachytherapy implant. Mediastinal and hilar lymph node staging was performed routinely in all patients. After clear margins were obtained grossly and on frozen section, a single-plane (125)I implant was designed to encompass a plane consisting of the staple line and a 2-cm margin of surrounding visceral pleura. The implant was introduced through the surgical incision and sutured to the visceral pleura. A prescribed dose of 100-120 y was delivered to a volume within 0.5 cm rom the plane of the implant. Follow-up orthogonal films or CTs were obtained for dosimetric analysis. Kaplan-Meier analyses were used to estimate the local control, locoregional control, and overall survival rates. RESULTS: Of the 110 patients, 65 had stage IA and 45 had stage IB NSCLC. The mean preoperative FEV(1) was 47% of the predicted volume. With a median follow-up of 11 months (range 1-68 months), there were four recurrences within the radiation volume. The estimated 5-year local (in-field) control, locoregional control, and overall survival rates were 90%, 61%, and 18%, respectively. CONCLUSION: Vicryl mesh brachytherapy after sublobar resection for high-risk stage I NSCLC patients is a feasible procedure, which results in an excellent local (in-field) control rate. FAU - Voynov, George AU - Voynov G AD - Department of Radiation Oncology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA. FAU - Heron, Dwight E AU - Heron DE FAU - Lin, Chyongchiou J AU - Lin CJ FAU - Burton, Steven AU - Burton S FAU - Chen, Alex AU - Chen A FAU - Quinn, Annette AU - Quinn A FAU - Santos, Ricardo AU - Santos R FAU - Colonias, Athanasios AU - Colonias A FAU - Landreneau, Rodney J AU - Landreneau RJ LA - eng PT - Journal Article PL - United States TA - Brachytherapy JT - Brachytherapy JID - 101137600 RN - 0 (Iodine Radioisotopes) RN - 34346-01-5 (Polyglactin 910) SB - IM MH - Aged MH - Aged, 80 and over MH - *Brachytherapy MH - Carcinoma, Non-Small-Cell Lung/pathology/physiopathology/radiotherapy/surgery/*therapy MH - Combined Modality Therapy MH - Female MH - Follow-Up Studies MH - Forced Expiratory Volume MH - Humans MH - *Intraoperative Care MH - Iodine Radioisotopes/administration & dosage/*therapeutic use MH - Lung Neoplasms/pathology/physiopathology/radiotherapy/surgery/*therapy MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/prevention & control MH - Neoplasm Staging MH - *Pneumonectomy/adverse effects/methods MH - Polyglactin 910/administration & dosage/*therapeutic use MH - Risk Factors MH - Survival Analysis MH - Thoracic Surgery, Video-Assisted MH - Thoracotomy MH - Time Factors MH - Treatment Outcome EDAT- 2005/12/14 09:00 MHDA- 2006/09/15 09:00 CRDT- 2005/12/14 09:00 PHST- 2005/01/06 00:00 [received] PHST- 2005/02/25 00:00 [revised] PHST- 2005/03/08 00:00 [accepted] PHST- 2005/12/14 09:00 [pubmed] PHST- 2006/09/15 09:00 [medline] PHST- 2005/12/14 09:00 [entrez] AID - S1538-4721(05)00100-5 [pii] AID - 10.1016/j.brachy.2005.03.007 [doi] PST - ppublish SO - Brachytherapy. 2005;4(4):278-85. doi: 10.1016/j.brachy.2005.03.007.